11:47 AM EDT, 05/08/2026 (MT Newswires) -- Gilead Sciences (GILD) raised Yeztugo guidance for 2026 to $1 billion from $800 million, which is "good enough"for the stock, since Q1 Yeztugo sales were in line with consensus but likely below investor expectations, Morgan Stanley said Friday.

Gilead raised total product sales guidance to $30 billion to $30.4 billion from $29.6 billion to $30 billion previously, versus Morgan Stanley's estimate of $30.3 billion and consensus of $30.2 billion, according to the firm. This excludes unchanged Veklury sales of $600 million, the brokerage said.

The company guided to non-GAAP loss per share of $0.65 to $1.05, down from the prior EPS forecast of $8.45 to $8.85, driven by in-process research and development expenses tied to recent acquisitions, the firm said. This compares with Morgan Stanley's $0.68 loss estimate and $8.55 EPS consensus, according to the note.

Morgan Stanley kept an overweight rating on Gilead Sciences and lowered the price target to $168 from $175.

Price: 131.19, Change: -2.87, Percent Change: -2.14